PainReform Ltd. (PRFX)
NASDAQ: PRFX · Real-Time Price · USD
2.300
-0.060 (-2.54%)
May 5, 2025, 4:00 PM EDT - Market closed
PainReform Employees
As of December 31, 2024, PainReform had 6 total employees, including 2 full-time and 4 part-time employees. The number of employees decreased by 1 or -14.29% compared to the previous year.
Employees
6
Change (1Y)
-1
Growth (1Y)
-14.29%
Revenue / Employee
n/a
Profits / Employee
-$2,431,333
Market Cap
3.92M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 6 | -1 | -14.29% |
| Dec 31, 2023 | 7 | 1 | 16.67% |
| Dec 31, 2022 | 6 | 2 | 50.00% |
| Dec 31, 2021 | 4 | 2 | 100.00% |
| Dec 31, 2020 | 2 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 94,300 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
| AbbVie | 55,000 |
PRFX News
- 25 days ago - PainReform Expands into Home Energy Management Sector, Leveraging DeepSolar's AI-Driven Platform to Address the Growing Solar Optimization Market - GlobeNewsWire
- 4 weeks ago - PainReform Provides Year-End Business Update - GlobeNewsWire
- 2 months ago - PainReform Completes Strategic Acquisition of DeepSolar, Unlocking New Growth Opportunities in AI-Driven Solar Analytics - GlobeNewsWire
- 2 months ago - PainReform Executes Definitive Agreement to Acquire DeepSolar, Marking a Unique Expansion Opportunity - GlobeNewsWire
- 4 months ago - PainReform Provides Further Update on Phase 3 Clinical Trial of PRF-110 - GlobeNewsWire
- 5 months ago - PainReform Announces Initial Topline Data for PRF-110 Phase 3 Clinical Trial - GlobeNewsWire
- 6 months ago - PainReform Announces Receipt of Nasdaq Notice Regarding Minimum Stockholders' Equity Requirement - GlobeNewsWire
- 8 months ago - PainReform Ltd. Confirms Sutures Compatibility in Human Clinical Trials for PRF-110 - GlobeNewsWire